Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for PTGX
| Stock Name | Protagonist Therapeutics Inc |
| Ticker | PTGX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US74366E1029 |
Show aggregate PTGX holdings
News associated with PTGX
- Protagonist Therapeutics (NASDAQ:PTGX) Now Covered by Barclays
- Barclays began coverage on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $72.00 price target on the stock. Several other research firms have also issued reports on PTGX. JMP Securities increased their target price on […] - 2025-09-19 02:36:48
- HC Wainwright Reiterates Buy Rating for Protagonist Therapeutics (NASDAQ:PTGX)
- Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $80.00 price target on the stock. HC Wainwright’s price objective indicates a potential upside of 28.74% from the stock’s previous close. A number of other […] - 2025-09-19 02:36:47
- Protagonist Therapeutics (NASDAQ:PTGX) Upgraded at Leerink Partnrs
- Leerink Partnrs upgraded shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) to a strong-buy rating in a research report released on Friday morning,Zacks.com reports. Leerink Partnrs also issued estimates for Protagonist Therapeutics’ Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.61) EPS and FY2025 earnings at ($1.95) EPS. A number of other analysts […] - 2025-09-15 02:47:57
- We Did The Math IJR Can Go To $133
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-28 09:18:11
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Mutual of America Capital Management LLC
- Mutual of America Capital Management LLC decreased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 3.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 8,679 shares of the company’s stock after selling 348 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Protagonist Therapeutics were […] - 2025-08-13 05:45:10
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Given Consensus Rating of “Buy” by Analysts
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been given a consensus recommendation of “Buy” by the nine research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation […] - 2025-08-08 04:42:56
- Jefferies Financial Group Inc. Sells 857,602 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Jefferies Financial Group Inc. lessened its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 57.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 631,893 shares of the company’s stock after selling 857,602 shares during the period. Jefferies Financial Group Inc.’s holdings in Protagonist Therapeutics were worth $30,558,000 as of […] - 2025-08-01 05:38:53
- Royce & Associates LP Buys New Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Royce & Associates LP bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,255 shares of the company’s stock, valued at approximately $593,000. A number of other hedge funds […] - 2025-07-30 04:49:05
- XSMO's Underlying Holdings Could Mean 15% Gain Potential
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 08:27:31
- Dinesh V. Ph D. Patel Sells 12,859 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 12,859 shares of the company’s stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $54.86, for a total value of $705,444.74. Following the sale, the chief executive officer owned 570,603 shares in […] - 2025-07-25 06:28:57
- Dinesh V. Ph D. Patel Sells 17,520 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 17,520 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $54.79, for a total transaction of $959,920.80. Following the transaction, the chief executive officer owned 531,018 shares in the […] - 2025-07-25 05:42:54
- Massachusetts Financial Services Co. MA Sells 723 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Massachusetts Financial Services Co. MA trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,726 shares of the company’s stock after selling 723 shares […] - 2025-07-21 05:51:00
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Holdings Lowered by Teacher Retirement System of Texas
- Teacher Retirement System of Texas trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 8.2% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 12,025 shares of the company’s stock after selling 1,074 shares during the period. Teacher Retirement System […] - 2025-07-16 04:34:43
- Amalgamated Bank Sells 467 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Amalgamated Bank cut its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,938 shares of the company’s stock after selling 467 shares during the quarter. Amalgamated Bank’s holdings […] - 2025-07-10 05:10:51
- GAMMA Investing LLC Has $58,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- GAMMA Investing LLC grew its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 153.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,203 shares of the company’s stock after buying an additional 728 shares during the period. GAMMA Investing […] - 2025-07-10 04:14:49
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of “Buy” from Analysts
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the […] - 2025-07-09 04:43:49
- Oregon Public Employees Retirement Fund Has $663,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Oregon Public Employees Retirement Fund cut its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 2.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 13,700 shares of the company’s stock after selling 300 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in […] - 2025-07-08 05:24:51
- Illinois Municipal Retirement Fund Sells 14,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Illinois Municipal Retirement Fund cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 41.8% in the 1st quarter, Holdings Channel.com reports. The fund owned 19,509 shares of the company’s stock after selling 14,000 shares during the period. Illinois Municipal Retirement Fund’s holdings in Protagonist Therapeutics were worth $943,000 as of […] - 2025-07-02 05:28:54
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by California State Teachers Retirement System
- California State Teachers Retirement System cut its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 42,349 shares of the company’s stock after selling 316 shares during the quarter. California State Teachers Retirement System’s holdings in Protagonist Therapeutics were worth […] - 2025-06-09 05:00:56
- Tidal Investments LLC Decreases Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Tidal Investments LLC trimmed its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.8% in the 4th quarter, Holdings Channel.com reports. The firm owned 21,012 shares of the company’s stock after selling 1,050 shares during the period. Tidal Investments LLC’s holdings in Protagonist Therapeutics were worth $811,000 at the end of the most […] - 2025-05-27 05:22:57
- Brokerages Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44
- Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have been given an average recommendation of “Buy” by the nine research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to […] - 2025-05-23 03:14:53
- Protagonist Therapeutics (NASDAQ:PTGX) Earns “Buy” Rating from HC Wainwright
- Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday,Benzinga reports. They presently have a $80.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 71.64% from the stock’s previous close. Other equities research analysts […] - 2025-05-21 03:03:18
- Deutsche Bank AG Acquires 17,763 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Deutsche Bank AG increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 14.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 137,932 shares of the company’s stock after purchasing an additional 17,763 shares during […] - 2025-05-19 05:10:57
- Comerica Bank Trims Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Comerica Bank decreased its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 20,558 shares of the company’s stock after selling 346 shares during the period. Comerica Bank’s holdings in Protagonist Therapeutics were worth $794,000 at the end of the most […] - 2025-05-14 05:20:53
- Marshall Wace LLP Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Marshall Wace LLP trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 93.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the company’s stock after selling 295,657 shares during the quarter. […] - 2025-05-02 05:30:50
- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Mariner LLC
- Mariner LLC increased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 12.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 17,983 shares of the company’s stock after buying an additional 2,004 shares during the period. Mariner LLC’s holdings in Protagonist Therapeutics were worth […] - 2025-04-30 05:19:01
- Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Target Price at $65.44
- Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) have earned a consensus recommendation of “Buy” from the nine research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation […] - 2025-04-28 02:22:54
- Barclays PLC Decreases Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Barclays PLC reduced its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 126,733 shares of the company’s stock after selling 262 shares during the period. Barclays PLC’s holdings in Protagonist Therapeutics were worth $4,891,000 as of its most recent SEC filing. A […] - 2025-04-27 05:24:54
- Bank of Montreal Can Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Bank of Montreal Can grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 4.5% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 6,250 shares of the company’s stock after acquiring an additional 270 shares during the quarter. Bank of Montreal Can’s holdings in Protagonist Therapeutics were worth $241,000 […] - 2025-04-25 04:36:55
- Geode Capital Management LLC Acquires 2,366 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
- Geode Capital Management LLC raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,377,063 shares of the company’s stock after purchasing an additional 2,366 shares during the quarter. […] - 2025-04-14 05:00:52
iShares MSCI World Small Cap UCITS ETF USD (Acc) PTGX holdings
| Date | Number of PTGX Shares Held | Base Market Value of PTGX Shares | Local Market Value of PTGX Shares | Change in PTGX Shares Held | Change in PTGX Base Value | Current Price per PTGX Share Held | Previous Price per PTGX Share Held |
|---|
| 2025-11-27 (Thursday) | 41,177 | USD 3,708,812 | USD 3,708,812 | 0 | USD 0 | USD 90.07 | USD 90.07 |
| 2025-11-26 (Wednesday) | 41,177 | USD 3,708,812 | USD 3,708,812 | -77 | USD 1,728 | USD 90.07 | USD 89.86 |
| 2025-11-25 (Tuesday) | 41,254 | USD 3,707,084 | USD 3,707,084 | 0 | USD 89,521 | USD 89.86 | USD 87.69 |
| 2025-11-24 (Monday) | 41,254 | USD 3,617,563 | USD 3,617,563 | 0 | USD 94,471 | USD 87.69 | USD 85.4 |
| 2025-11-21 (Friday) | 41,254 | USD 3,523,092 | USD 3,523,092 | 0 | USD 49,505 | USD 85.4 | USD 84.2 |
| 2025-11-20 (Thursday) | 41,254 | USD 3,473,587 | USD 3,473,587 | 237 | USD -18,190 | USD 84.2 | USD 85.13 |
| 2025-11-19 (Wednesday) | 41,017 | USD 3,491,777 | USD 3,491,777 | 2,370 | USD 230,357 | USD 85.13 | USD 84.39 |
| 2025-11-18 (Tuesday) | 38,647 | USD 3,261,420 | USD 3,261,420 | 0 | USD -14,686 | USD 84.39 | USD 84.77 |
| 2025-11-17 (Monday) | 38,647 | USD 3,276,106 | USD 3,276,106 | 0 | USD 6,183 | USD 84.77 | USD 84.61 |
| 2025-11-14 (Friday) | 38,647 | USD 3,269,923 | USD 3,269,923 | -308 | USD 27,309 | USD 84.61 | USD 83.24 |
| 2025-11-13 (Thursday) | 38,955 | USD 3,242,614 | USD 3,242,614 | 0 | USD -62,718 | USD 83.24 | USD 84.85 |
| 2025-11-12 (Wednesday) | 38,955 | USD 3,305,332 | USD 3,305,332 | 0 | USD -27,658 | USD 84.85 | USD 85.56 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of PTGX by Blackrock for IE00BF4RFH31
Show aggregate share trades of PTGX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-11-26 | SELL | -77 | 90.850 | 89.500 | 89.635 | USD -6,902 | 51.63 Loss of -2,926 on sale |
| 2025-11-26 | SELL | -77 | 90.850 | 89.500 | 89.635 | USD -6,902 | 51.63 Loss of -2,926 on sale |
| 2025-11-20 | BUY | 237 | | | 84.200* | | 51.00 |
| 2025-11-19 | BUY | 2,370 | | | 85.130* | | 50.84 |
| 2025-11-14 | SELL | -308 | 85.900 | 82.060 | 82.444 | USD -25,393 | 50.38 Loss of -9,876 on sale |
| 2025-10-29 | BUY | 154 | 76.690 | 79.000 | 78.769 | USD 12,130 | 48.65 |
| 2025-10-21 | BUY | 308 | 75.000 | 77.220 | 76.998 | USD 23,715 | 47.86 |
| 2025-10-07 | BUY | 154 | 65.470 | 65.840 | 65.803 | USD 10,134 | 47.47 |
| 2025-09-08 | SELL | -312 | 56.190 | 59.500 | 59.169 | USD -18,461 | 46.61 Loss of -3,919 on sale |
| 2025-08-15 | BUY | 154 | 56.070 | 56.325 | 56.300 | USD 8,670 | 46.56 |
| 2025-08-07 | BUY | 462 | 50.960 | 54.810 | 54.425 | USD 25,144 | 46.48 |
| 2025-07-29 | BUY | 154 | 55.010 | 57.145 | 56.932 | USD 8,767 | 46.22 |
| 2025-07-14 | BUY | 312 | 55.230 | 55.410 | 55.392 | USD 17,282 | 45.85 |
| 2025-06-30 | BUY | 312 | 55.270 | 57.235 | 57.039 | USD 17,796 | 45.58 |
| 2025-06-25 | BUY | 468 | 54.440 | 54.955 | 54.904 | USD 25,695 | 45.40 |
| 2025-06-20 | SELL | -78 | 53.340 | 54.970 | 54.807 | USD -4,275 | 45.25 Loss of -745 on sale |
| 2025-06-12 | SELL | -624 | 56.320 | 56.675 | 56.639 | USD -35,343 | 44.86 Loss of -7,348 on sale |
| 2025-06-02 | BUY | 234 | 50.150 | 50.225 | 50.217 | USD 11,751 | 44.38 |
| 2025-05-28 | BUY | 156 | 45.750 | 46.850 | 46.740 | USD 7,291 | 44.33 |
| 2025-05-14 | BUY | 78 | 43.770 | 45.257 | 45.108 | USD 3,518 | 44.24 |
| 2025-05-13 | BUY | 156 | 44.270 | 45.230 | 45.134 | USD 7,041 | 44.24 |
| 2025-05-07 | BUY | 234 | 43.090 | 43.200 | 43.189 | USD 10,106 | 44.26 |
| 2025-04-28 | BUY | 78 | 44.390 | 45.495 | 45.384 | USD 3,540 | 44.23 |
| 2025-04-16 | BUY | 1,014 | 45.800 | 47.140 | 47.006 | USD 47,664 | 44.13 |
| 2025-04-14 | BUY | 156 | 45.030 | 45.510 | 45.462 | USD 7,092 | 44.09 |
| 2025-04-08 | SELL | -156 | 41.670 | 45.880 | 45.459 | USD -7,092 | 44.18 Loss of -200 on sale |
| 2025-04-04 | SELL | -158 | 44.440 | 46.450 | 46.249 | USD -7,307 | 44.18 Loss of -326 on sale |
| 2025-03-28 | BUY | 780 | 48.880 | 50.480 | 50.320 | USD 39,250 | 44.03 |
| 2025-03-12 | SELL | -156 | 57.650 | 60.600 | 60.305 | USD -9,408 | 42.77 Loss of -2,735 on sale |
| 2025-03-04 | SELL | -158 | 38.660 | 39.700 | 39.596 | USD -6,256 | 42.56 Profit of 468 on sale |
| 2025-02-26 | SELL | -316 | 36.150 | 36.250 | 36.240 | USD -11,452 | 42.84 Profit of 2,085 on sale |
| 2025-02-13 | BUY | 80 | 38.680 | 38.720 | 38.716 | USD 3,097 | 43.49 |
| 2025-02-12 | BUY | 320 | 37.420 | 37.540 | 37.528 | USD 12,009 | 43.58 |
| 2025-01-27 | BUY | 79 | 38.360 | 39.890 | 39.737 | USD 3,139 | 44.77 |
| 2025-01-23 | BUY | 79 | 37.800 | 37.940 | 37.926 | USD 2,996 | 45.03 |
| 2024-12-09 | BUY | 2,880 | 40.500 | 42.580 | 42.372 | USD 122,031 | 45.51 |
| 2024-12-04 | BUY | 158 | 40.580 | 42.180 | 42.020 | USD 6,639 | 45.77 |
| 2024-12-03 | BUY | 237 | 41.250 | 43.490 | 43.266 | USD 10,254 | 45.87 |
| 2024-11-19 | BUY | 474 | 38.650 | 39.820 | 39.703 | USD 18,819 | 46.61 |
| 2024-11-18 | BUY | 158 | 40.390 | 41.050 | 40.984 | USD 6,475 | 46.80 |
| 2024-11-12 | BUY | 316 | 43.170 | 46.640 | 46.293 | USD 14,629 | 46.92 |
| 2024-11-11 | BUY | 78 | 46.500 | 48.350 | 48.165 | USD 3,757 | 46.94 |
| 2024-11-11 | BUY | 78 | 46.500 | 48.350 | 48.165 | USD 3,757 | 46.94 |
| 2024-11-07 | BUY | 390 | 47.610 | 48.690 | 48.582 | USD 18,947 | 46.95 |
| 2024-11-07 | BUY | 390 | 47.610 | 48.690 | 48.582 | USD 18,947 | 46.95 |
| 2024-10-23 | BUY | 156 | 46.590 | 46.680 | 46.671 | USD 7,281 | 46.20 |
| 2024-10-23 | BUY | 156 | 46.590 | 46.680 | 46.671 | USD 7,281 | 46.20 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of PTGX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 204,101 | 2,581 | 524,512 | 38.9% |
| 2025-09-18 | 261,238 | 603 | 538,967 | 48.5% |
| 2025-09-17 | 160,871 | 455 | 278,662 | 57.7% |
| 2025-09-16 | 119,487 | 213 | 179,491 | 66.6% |
| 2025-09-15 | 164,481 | 90 | 265,275 | 62.0% |
| 2025-09-12 | 129,277 | 1,000 | 230,328 | 56.1% |
| 2025-09-11 | 242,764 | 0 | 391,638 | 62.0% |
| 2025-09-10 | 158,669 | 1,425 | 254,846 | 62.3% |
| 2025-09-09 | 425,476 | 500 | 622,218 | 68.4% |
| 2025-09-08 | 528,123 | 800 | 611,363 | 86.4% |
| 2025-09-05 | 518,633 | 11,824 | 804,839 | 64.4% |
| 2025-09-04 | 337,385 | 2,916 | 576,292 | 58.5% |
| 2025-09-03 | 195,570 | 1,053 | 372,182 | 52.5% |
| 2025-09-02 | 188,399 | 0 | 271,348 | 69.4% |
| 2025-08-29 | 165,571 | 500 | 265,840 | 62.3% |
| 2025-08-28 | 272,112 | 902 | 423,847 | 64.2% |
| 2025-08-27 | 322,274 | 11,729 | 514,925 | 62.6% |
| 2025-08-26 | 67,797 | 3 | 206,573 | 32.8% |
| 2025-08-25 | 108,118 | 1,807 | 147,926 | 73.1% |
| 2025-08-22 | 92,580 | 0 | 136,504 | 67.8% |
| 2025-08-21 | 67,903 | 732 | 226,490 | 30.0% |
| 2025-08-20 | 137,747 | 4,436 | 275,169 | 50.1% |
| 2025-08-19 | 108,591 | 2,229 | 172,546 | 62.9% |
| 2025-08-18 | 145,066 | 89 | 190,752 | 76.0% |
| 2025-08-15 | 102,863 | 1,000 | 136,937 | 75.1% |
| 2025-08-14 | 166,263 | 0 | 194,337 | 85.6% |
| 2025-08-13 | 142,989 | 4,887 | 265,978 | 53.8% |
| 2025-08-12 | 119,666 | 1,400 | 138,812 | 86.2% |
| 2025-08-11 | 161,809 | 0 | 224,270 | 72.1% |
| 2025-08-08 | 126,345 | 380 | 200,061 | 63.2% |
| 2025-08-07 | 250,926 | 10 | 327,014 | 76.7% |
| 2025-08-06 | 118,632 | 274 | 136,885 | 86.7% |
| 2025-08-05 | 95,352 | 5 | 128,071 | 74.5% |
| 2025-08-04 | 107,663 | 3,147 | 140,665 | 76.5% |
| 2025-08-01 | 102,643 | 0 | 185,382 | 55.4% |
| 2025-07-31 | 134,674 | 26,403 | 236,093 | 57.0% |
| 2025-07-30 | 88,986 | 1,477 | 128,497 | 69.3% |
| 2025-07-29 | 108,417 | 242 | 253,165 | 42.8% |
| 2025-07-28 | 195,264 | 19 | 241,347 | 80.9% |
| 2025-07-25 | 117,334 | 156 | 198,470 | 59.1% |
| 2025-07-24 | 191,250 | 125 | 255,624 | 74.8% |
| 2025-07-23 | 393,783 | 53 | 542,672 | 72.6% |
| 2025-07-22 | 117,379 | 20,048 | 158,451 | 74.1% |
| 2025-07-21 | 92,245 | 93 | 135,809 | 67.9% |
| 2025-07-18 | 93,308 | 98 | 145,564 | 64.1% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.